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Purpose: The ZOTECT study assesses the effect of zoledronic acid (ZOL) on bone-marker levels and
potential correlations with disease outcomes in bisphosphonate-naive patients.
Methods: This prospective, single-arm, open-label study in bisphosphonate-naive (Z6 months) patients
with bone metastases from prostate cancer (PC; n¼301) or breast cancer (BC; n¼99) enrolled at 98
German sites (May 2006 to July 2008) investigated the effect of ZOL (4 mg intravenously every 4 week-
s4 months, with a ﬁnal follow-up at 12 months) on bone-marker levels. Secondary assessments: skeletal-
related event (SRE) rate, pain, quality of life (QoL), and prostate-speciﬁc antigen levels. Endpoints were
assessed using summary statistics by visit/tumor type and Kaplan–Meier analyses.
Results: ZOL treatment signiﬁcantly decreased bone-marker levels (amino-terminal propeptide of type I
collagen [P1NP], C-terminal cross-linking telopeptide of type I collagen [CTX]; Po0.0001), and this
decrease was maintained through the ﬁnal 1-year follow-up visit. Baseline P1NP and CTX levels correlated
with extent of bone disease (Po0.0001, each) and on-treatment decreases in marker levels. Skeletal disease
burden and bone-marker levels were similar between PC and BC patients, and ZOL did not signiﬁcantly
inﬂuence osteoprotegerin/receptor activator of nuclear factor-kB ligand levels. Only 13 SREs occurred in 11
patients, supporting the known ZOL-mediated reduction in SREs. On-treatment bone-marker level changes
did not correlate with SRE rate, pain scores, or QoL. Generally, ZOL was well tolerated and adverse events
were consistent with its known safety proﬁle.
Conclusions: This study conﬁrms that ZOL therapy signiﬁcantly reduces bone turnover (measured as P1NP
and CTX levels) in patients with bone metastases from PC or BC.
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Up to 75% of patients with advanced prostate cancer (PC)
or breast cancer (BC) will develop bone metastases, which dysre-
gulate normal bone metabolism [1]. Without antiresorptive thera-
pies, most patients with bone metastases will experience
potentially debilitating skeletal-related events (SREs: pathologic
fractures, spinal cord compression, hypercalcemia, the need for
surgery to bone, or severe bone pain requiring palliative radio-
therapy) [1,2]. Zoledronic acid (ZOL) is a nitrogen-containing
bisphosphonate and potent osteoclast inhibitor. Treatment with
ZOL reduces the risk of SREs and suppresses pathologic bone
turnover in patients with multiple myeloma or bone metastases
from solid tumors, including PC and BC [3–5].ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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peptides released during the bone remodeling process, which can
be measured in the urine or blood and are potentially useful for
assessing the overall state of bone turnover [6]. For example,
amino-terminal propeptide of type I collagen (P1NP), serum
C-terminal cross-linking telopeptide of type I collagen (CTX),
and urinary N-telopeptide (NTX) is physiologic byproducts of
bone remodeling. Elevated levels of CTX or NTX are common in
patients with osteolytic bone lesions; thus, these markers may
reﬂect increased osteolysis (osteoclast-mediated bone resorp-
tion), which is more pronounced in BC. The bone formation
marker P1NP is elevated in osteoblastic or mixed osteolytic–
osteoblastic lesions, as occurs with PC. Other important markers
of bone turnover include modulators of osteoclast activity, such
as the receptor activator of nuclear factor-kB ligand (RANKL) and
osteoprotegerin (OPG). Osteoprotegerin is a physiologic inhibitor
of RANKL, an inducer of osteoclast activity.
Elevated levels of bone turnover markers (e.g., NTX and CTX)
have been associated with poor clinical outcomes in patients with
cancer [7–9], including increased SRE risk [7,8]. Moreover, anti-
resorptive therapies have been shown to reduce bone turnover
marker levels in patients with cancer [10,11]. Retrospective ana-
lyses of data from phase 3 trials of ZOL versus control (i.e., placebo
for PC, pamidronate for BC) in patients with bone metastases from
castration-resistant PC (N¼314) or BC (N¼379) showed that ZOL
normalized NTX levels within 3 months in most patients (70% PC,
81% BC) who had high baseline NTX levels (PC, n¼193; BC, n¼220)
[11]. Moreover, ZOL-mediated normalization of NTX levels within
3 months of treatment was associated with decreased risks of ﬁrst
SRE (40% decrease; Pr0.04) and death (PC, 59% decrease;
Po0.0001) versus persistently increased NTX levels [11]. Further
retrospective analyses of this trial database also showed that ZOL
therapy was associated with improved survival in patients with
aggressive bone disease [12]. Thus, modulating bone turnover with
ZOL may improve clinical outcomes in patients with advanced
cancer. Here we present results from the ZOTECT study
(NCT00334139), which assessed the effect of ZOL therapy on bone
turnover and potential correlations with disease outcomes.2. Patients and methods
2.1. Study design and treatment
This prospective, single-arm, open-label study examined the
effect of ZOL on bone turnover marker levels in patients who were
bisphosphonate naive for at least 6 months with bone metastases
from PC or BC recruited between May 2006 and July 2008. The
patients received four doses of ZOL (4 mg every 4 weeks); con-
tinued treatment with ZOL was recommended (but not mandatory)
afterward. All patients were advised to take 500-mg calcium
supplements and a multivitamin tablet daily. Patients also received
concomitant anticancer therapy as determined by the treating
physician.
Bone turnover markers (CTX, P1NP, RANKL, and OPG) and
prostate-speciﬁc antigen (PSA) levels were measured at baseline,
monthly through 120 days (study end), and at the ﬁnal 1-year
follow-up visit (360 days; Fig. 1). No data were systematically
collected between the 120-day visit and the 1-year follow-up
(360-day visit). Laboratory measurements (PSA [patients with PC]
and bone markers [all patients]) were performed at a single
laboratory (Marburg, Germany). Bone scans were performed at
baseline to determine the extent of bone disease, and SREs were
assessed at baseline, on-study (visits 2–5), and at study end (visit
6). Pain was evaluated using visual analogue scale (VAS) and
analgesic scores. Quality of life (QoL) was measured using theEuropean Organisation for Research and Treatment of Cancer
(EORTC) C-30 and BR-23 modules.
2.2. Patients
2.2.1. Inclusion criteria
All patients had histologically proven PC or BC with one or more
cancer-related bone lesions, with or without hormonal therapy.
Standard concomitant anticancer therapy was allowed, including
prior surgery, chemotherapy, and radiotherapy (completed Z4
weeks before enrollment). Additional requirements included
Eastern Cooperative Oncology Group (ECOG) performance status of
0–2, normal cardiac function, life expectancy of Z6 months, total
bilirubin r2.5 times the upper limit of normal (ULN), normal
serum glutamic pyruvic transaminase, serum glutamic-oxaloacetic
transaminase r2.5 times the ULN, and creatinine clearance (CrCl)
Z30 mL/min (Cockcroft–Gault formula). A negative pregnancy test
at screening was required for women of childbearing potential. All
patients were Z18 years of age at study entry, signed informed
consent before study entry, and were accessible for treatment
during the study.
This clinical study was designed, implemented, and reported
in accordance with the International Conference on Harmonisa-
tion’s Harmonised Tripartite Guidelines for Good Clinical Practice,
with applicable local regulations (including European Directive
2001/83/EC and US Code of Federal Regulations Part 21), and with
the ethical principles laid down in the Declaration of Helsinki.
2.2.2. Exclusion criteria
Patients with prior bisphosphonate therapy within 6 months
of enrollment, known hypersensitivity to ZOL or other bisphos-
phonates, or previous radiation therapy to bone (including ther-
apeutic radioisotopes such as strontium-89) within 1 month were
excluded. To reduce the risk of osteonecrosis of the jaw, patients
with current or active dental problems or recent/planned dental
surgery were excluded. Other exclusion criteria included no
detectable cancer-related bone lesions (bone radiographs or bone
scan) or the presence of symptomatic brain metastases, renal
impairment (CrCl o30 mL/min), abnormal calcium levels (cor-
rected serum calcium o8.0 mg/dL or Z12.0 mg/dL), history of
diseases that inﬂuence bone metabolism (e.g., Paget’s disease,
primary hyperparathyroidism), or osteoporosis (T-scorer2.5)
requiring antiresorptive therapy. Exclusions speciﬁc to women
included breastfeeding, pregnancy, or failure to use at least one
medically acceptable contraception method.
2.3. Key endpoints
The primary endpoint of this trial was the course of changes in
bone turnover marker levels (CTX, P1NP, RANKL, OPG) during and
after ZOL therapy. Secondary endpoints included pain (VAS and
analgesic scores), rate of SREs (excluding hypocalcemia), PSA
course (PC cohort), QoL, safety, tolerability, and potential relation-
ships between baseline bone marker levels and clinical disease
parameters (extent of disease, pain, and SREs).
2.4. Statistical analyses
Analyses of these data were exploratory (i.e., hypothesis
generating rather than hypothesis conﬁrming). Summary statis-
tics (intent-to-treat [ITT] and per-protocol populations) for abso-
lute values and changes from baseline were calculated by visit
and tumor type. Data were transformed using natural log (origi-
nal value þ1) to adjust for skewed distributions. Time-to-event
variables (time to ﬁrst SRE and overall survival) were analyzed
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Fig. 1. Trial visit schedule. Bone turnover marker levels and progression-free survival were measured at 1 day (visit 2), monthly through 120 day (visits 3–6), and at 360
day (ﬁnal 1-year follow-up, visit 7); ZOL (4 mg intravenously q 4 weeks) was administered on visits 2–5. q 4 weeks, every 4 weeks; ZOL, zoledronic acid.
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Fig. 2. CONSORT diagram. AE, adverse event; BP, bisphosphonate; BC, breast
cancer; ITT, intent-to-treat; PC, prostate cancer; ZOL, zoledronic acid.
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5% signiﬁcance level (two-sided). Appropriate two-sided 95%
conﬁdence intervals were calculated for means and proportions
(Clopper and Pearson method). Missing values were replaced by
the last observation carried forward. Safety assessments were
based on frequency and type of adverse events (AEs) and changes
in laboratory values.3. Results
3.1. Patients
Patients with PC (n¼301) or BC (n¼99) were enrolled at 98
German sites between May 2006 and July 2008. Of the 400
treated patients, 335 completed the study (Fig. 2). A total of 65
patients discontinued the study because of death (n¼17), with-
drawn consent (n¼15), AEs (n¼11), protocol violations (n¼9), or
other reasons (n¼13). The entire ITT population (n¼397) wasanalyzed and is composed of patients who received at least one
ZOL dose and had one postbaseline bone marker assessment.
Furthermore, within the ITT population, 276 patients were trea-
ted per protocol (i.e., had no major protocol violations). Two
patients were excluded for bisphosphonate use within 6 months
before study entry (1 ZOL and 1 clodronate). Baseline patient
demographics and disease characteristics are summarized in
Table 1. Notably, at study entry 27 patients had experienced 30
SREs (PC: 15 patients with 17 SREs; BC: 12 patients with 13 SREs),
and baseline serum CTX and P1NP levels were higher in patients
with PC versus BC. Study-end (120-day) visit data were available
for 94% (n¼372) of the ITT population (n¼397) and 96% (n¼266)
of the per-protocol population (n¼276).
3.2. Bone turnover marker level changes
Therapy with ZOL decreased P1NP and CTX levels in 79% of
patients (Table 2), and these reductions were signiﬁcant (30 days,
60 days, or 90 days versus baseline; Po0.001 for all; 120 days
versus baseline; Po0.0001). The decreases in P1NP and CTX levels
were rapid and sustained through 360 days (Fig. 3), although ﬁnal
1-year follow-up visit data were available for only 50% of the
patients. No signiﬁcant changes were observed in mean OPG
(0.171.53 pmol/L) or RANKL (070.33 pmol/L) levels at 120 days
(end of study) compared with baseline (Wilcoxon P¼0.66, both).
There were no statistically signiﬁcant differences in bone marker
levels between patients with PC or BC throughout the study.
3.3. Correlations between bone turnover marker levels and clinical
parameters
3.3.1. Extent of disease at baseline
The extent of bone disease at baseline correlated with baseline
levels of P1NP and CTX. Greater extent of bone disease was associated
with elevated bone turnover marker levels (Fig. 4). Notably, patients
with a high extent of bone disease at baseline also recorded the
largest on-study reductions in bone marker levels (Table 3).
3.3.2. SREs, pain, and QoL
On-study SREs were infrequent, with 13 SREs recorded in 11
patients (2.8%). These SREs included spinal cord compression (4),
radiation to bone (4), pathologic fractures (3), and surgery to bone
(2). Patients reported small but signiﬁcant increases in pain levels, as
measured by analgesic scores (120 days versus baseline; P¼0.008).
Pain scores using the VAS remained nearly constant from visit 1
(26.1726.6; n¼158) to visit 6 (23.0724.3; n¼161). Signiﬁcant,
albeit numerically small, changes in reported QoLmeasures included
decreased physical functioning (2.7; Wilcoxon P¼0.018) and
Table 1
Patient baseline demographics and disease characteristics (ITT).
Total (N¼397) PC (n¼299) BC (n¼98)
Median age, years (range) 70 (30–85) 71 (48–85) 61 (30–82)
Sex, n (%)
Male 299 (75.3) 299 (100) 0
Female 98 (24.7) 0 98 (100)
Race, n (%)
Caucasian 383 (96.5) 292 (97.7) 91 (92.9)
Asian 1 (0.3) 0 1 (1.0)
Other 13 (3.3) 7 (2.3) 6 (6.1)
Prior therapy, n (%)
Radiation 129 (32.5) 75 (25.1) 54 (55.1)
Chemotherapy 133 (33.5) 65 (21.7) 68 (69.4)
Hormone therapy 342 (86.1) 270 (90.3) 72 (73.5)
Chemo- and hormone therapy 111 (28) 61 (20.4) 50 (51.0)
Surgery 215 (54.2) 133 (44.2) 82 (82.8)
Mean time from diagnosis to study entry, days (SD) 155.4 (366.4) 174.3 (382.2) 97.7 (308.0)
Extent of bone disease, n (%)
Normal bone scan 3 (0.8) 2 (0.7) 1 (1.0)
o6 Bone lesions 195 (49.1) 131 (43.8) 64 (65.3)
6–20 Bone lesions 118 (29.7) 93 (31.1) 25 (25.5)
420 Bone lesions butosuper scan 54 (13.6) 48 (16.1) 6 (6.1)
Super scan (75% of ribs, vertebrae, and pelvic bones have lesions) 24 (6.0) 23 (7.7) 1 (1.0)
Sites of extraskeletal metastases, n (%)
Lung 35 (8.8) 12 (4) 23 (23.5)
Liver 24 (6.0) 4 (1.3) 20 (20.4)
Lymph nodes 98 (24.7) 80 (26.8) 18 (18.4)
Other 19 (4.8) 10 (3.3) 9 (9.2)
Soft tissue 6 (1.5) 3 (1.0) 3 (3.1)
Not evaluated 251 (63.2) 207 (69.2) 44 (44.9)
Bone turnover marker levels, mean (SD) (n¼387) (n¼294) (n¼93)
P1NP (ng/mL) 227.1 (409.5) 268 (458.8) 97.9 (104)
CTX (ng/mL) 0.5 (0.53) 0.5 (0.58) 0.3 (0.28)
OPG (pmol/L) 5.6 (2.2) 5.8 (2.4) 5.1 (1.7)
RANKL (pmol/L) 0.1 (0.27) 0.1 (0.29) 0.1 (0.20)
PSA levels, mean (SD) (n¼294) (n¼294) N/A
PSA (mg/L) 168.5 (531.1) 168.5 (531.1) N/A
BC, breast cancer; CTX, serum C-terminal cross-linking telopeptide of type I collagen; ITT, intent-to-treat population; N/A, not applicable; OPG, osteoprotegerin; P1NP, amino-
terminal propeptide of type I collagen; PC, prostate cancer; PSA, prostate-speciﬁc antigen; RANKL, receptor activator of nuclear factor-kB ligand; SD, standard deviation.
Table 2
Patients’ relative change in bone turnover marker levels at 120 days/LOCF versus
baseline (ITT population).
Change from baselinea P1NP, n (%) CTX, n (%)
PC
m 48 (16.1) 45 (15.1)
k 235 (78.6) 238 (79.6)
No change 0 0
BC
m 8 (8.2) 3 (3.1)
k 81 (82.7) 85 (86.7)
No change 0 1 (1.0)
BC, breast cancer; CTX, serum C-terminal cross-linking telopeptide of type I
collagen; ITT, intent-to-treat; LOCF, last observation carried forward; PC, prostate
cancer; P1NP, amino-terminal propeptide of type I collagen.
a All values that were elevated relative to baseline were deﬁned as an increase.
All values that were reduced relative to baseline were deﬁned as a decrease.
P. Hadji et al. / Journal of Bone Oncology 1 (2012) 88–94 91increased global health status/QoL (þ3.2; Wilcoxon P¼0.019),
nausea/vomiting (þ2.3; Wilcoxon P¼0.030), dyspnea (þ5.0;
Wilcoxon P¼0.001), and ﬁnancial problems (þ3.1; Wilcoxon
P¼0.021). However, changes in bone turnover marker levels did
not correlate with SRE rate, pain, or QoL.
3.4. PSA
Prostate-speciﬁc antigen levels decreased with ZOL treatment
on study (Fig. 5), and mean PSA levels were lower at study end(120 days; 92.5 mg/L) than at baseline (168.5 mg/L; Wilcoxon
signed-rank test P¼0.27). At the ﬁnal 1-year follow-up visit,
PSA levels increased to 218.7 mg/L (visit 7; 360 days). Data
pertaining to bisphosphonate therapy and changes in anticancer
therapies between 120 days (study end) and 360 days (ﬁnal 1-year
follow-up) were not collected. Therefore, it is not known whether
ZOL was administered after completion of on-study therapy.
3.5. Safety
Generally, ZOL was well tolerated and AEs were consistent with
its known safety proﬁle. During the study, a total of 788 AEs were
reported in 249 patients (Table 4). The most frequently reported
AEs were bone pain (11.3%), nausea (8.3%), and fatigue (6.3%).
Osteonecrosis of the jaw occurred in 1 patient (PC patient with a
dental implant installed 412 months before beginning on-study
therapy). Renal failure occurred in 3 patients (all with PC); none
were suspected to be related to the study drug.4. Discussion
In the ZOTECT study, ZOL therapy was associated with signiﬁ-
cantly decreased P1NP and CTX levels within 1 month of initiating
treatment (Po0.0001) in patients with bone metastases from PC or
BC. These data support earlier evidence for ZOL-mediated normal-
ization of bone marker levels [7,8] and are consistent with explora-
tory analyses showing that ZOL therapy normalized elevated
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1-year follow-up. PC, prostate cancer; PSA, prostate-speciﬁc antigen; ZOL,
zoledronic acid.Table 3
Correlation of extent of disease at baseline and change in bone turnover markers
P1NP and CTX at 120 days versus baseline (per-protocol population).
Extent of disease at baseline Change in bone turnover
markers at 120 days versus
baseline
Patients
(n)
P1NP
(ng/mL)
CTX
(ng/mL)
PC
o6 Bone lesions 96 57.0 0.2
6–20 Bone lesions 68 234.5 0.3
420 Bone lesions butosuper scan 27 406.4 0.5
Super scan (75% of ribs, vertebrae, and pelvic
bones have lesions)
15 33.6 –0.2
BC
o6 Bone lesions 41 5.4 0.2
6–20 Bone lesions 13 30.1 0.2
420 Bone lesions but osuper scan 5 113.7 0.4
Super scan (75% of ribs, vertebrae, and pelvic
bones have lesions)
1 561.1 1.2
BC, breast cancer; CTX, serum C-terminal cross-linking telopeptide of type I
collagen; PC, prostate cancer; P1NP, amino-terminal propeptide of type I collagen.
0
50
100
150
200
250
300
P
1N
P
, n
g/
m
L
C
TX
, n
g/
m
L
Total
PC
BC
Time, days
0
0.1
0.2
0.3
0.4
0.5
0.6
Time, days
0 30 60 90 120 150 180 210 240 270 300 330 3600 30 60 90 120 150 180 210 240 270 300 330 360
Total
PC
BC
Fig. 3. ZOL decreased (a) P1NP and (b) CTX levels in patients with PC or BC during 4 months of therapy (per-protocol population). (a) Mean change in P1NP levels at 120
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P. Hadji et al. / Journal of Bone Oncology 1 (2012) 88–9492baseline NTX levels within 3months in 70% and 81% of patients with
PC or BC, respectively [11]. Furthermore, these data may be clinically
relevant because elevated bone turnover marker levels have been
associated with poor clinical outcomes [7,8], whereas rapid normal-
ization in marker levels has been associated with improved survival
in patients with cancer [11]. Consistent with earlier reports [11],
baseline CTX and P1NP levels were higher in PC patients than in BC
patients, thereby supporting the mixed rather than purely osteo-
blastic nature of PC bone lesions in our study.
In the present study, ZOL did not signiﬁcantly inﬂuence the
levels of RANKL (inducer of osteoclasts) or OPG (physiologic
inhibitor of RANKL). This is in contrast with data from a small
trial in patients with newly diagnosed bone metastases from PC,
BC, or lung cancer (N¼49), wherein ZOL reduced RANKL and
increased OPG levels at 12 months, although these changes were
not statistically signiﬁcant [14]. Because of our trial design (i.e.,
no assessments of bone marker levels and ZOL therapy not
required between 120 days and 360 days), late or transient
changes in RANKL or OPG levels may not have been detected.
Table 4
Adverse events (AEs) and serious adverse events (SAEs).a
Patients, n (%)
(N¼400)
All AEs 249 (62.3)
Suspected relationship to study drug 52 (13.0)
Led to dose adjustment or temporary treatment
interruption
4 (1.0)
Led to discontinuation 16 (4.0)
Required concomitant medication/nondrug therapy 155 (38.8)
SAEs 75 (18.8)
Death 17 (4.3)
SAEs with suspected relationship to study drug 4 (1.0)
SAEs leading to discontinuation 10 (2.5)
Frequent AEs (Z 2.8%; by preferred term)
Bone pain 45 (11.3)
Nausea 33 (8.3)
Fatigue 25 (6.3)
Back pain 19 (4.8)
Constipation 18 (4.5)
Vomiting 18 (4.5)
Chills 18 (4.5)
Pain in extremity 18 (4.5)
Pyrexia 16 (4.0)
Diarrhea 14 (3.5)
Tumor pain 12 (3.0)
Anemia 11 (2.8)
Arthralgia 11 (2.8)
Malignant neoplasm progression 11 (2.8)
Cough 11 (2.8)
a Safety population includes all enrolled patients who received at least one
dose of study drug.
P. Hadji et al. / Journal of Bone Oncology 1 (2012) 88–94 93In addition to decreased P1NP and CTX levels, PSA levels
continuously decreased during ZOL treatment in patients with
PC. Bone marker levels may be elevated in patients with PC
receiving androgen-deprivation therapy for locally advanced dis-
ease as well as in those with bone metastases [11,15], and
elevated bone marker levels have been correlated with treatment
failure (i.e., increasing PSA levels and progression of bone metas-
tases) [16]. Exploratory analyses of a phase 3 study in men with
bone metastases from castration-resistant PC [5,13] suggest a
trend for slower PSA progression with ZOL versus placebo [17].
Moreover, these analyses showed that PSA kinetics continued to
correlate with clinical outcomes regardless of treatment modal-
ities or the presence of bone disease [17]. Combined with our data
showing decreased PSA levels during ZOL treatment, these obser-
vations suggest that ZOL-mediated normalization of bone turn-
over marker levels also might inﬂuence disease outcome.
However, it should be noted that most patients with PC will not
receive ZOL until they develop castration-resistant PC.
A limitation of this study was the single-arm trial design (i.e.,
no placebo or control arm). In addition, not recording data,
particularly bisphosphonate use or anticancer therapy, between
the last on-study ZOL dose and the ﬁnal 1-year follow-up visit
limits the potential to analyze correlations between on-study
bone marker level changes and clinical outcomes. Despite these
limitations, the very low incidence of SREs reported in this study
(potentially a result of modern treatments for advanced BC and
PC, which may offer better disease control overall and in bone
compared with the treatment paradigms used in earlier trials of
bisphosphonates [3–5]) is important and should be considered
when interpreting ongoing studies or designing future trials.
5. Conclusions
These data conﬁrm that ZOL decreases bone resorption levels
in patients with bone metastases from PC or BC and supportassociations between bone marker levels and extent of bone
disease. Our observations are also consistent with earlier reports
of improved clinical outcomes with rapid normalization of bone
marker levels during ZOL treatment.Role of the funding source
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